CAS: 42042-68-2; 4-(Methylamino)Butan-1-Ol

上下游产品

CAS号37941-69-8 4-羟基-N-甲基丁酰胺 | CAS号13325-10-5 4-氨基-1-丁醇 | CAS号109-94-4 甲酸乙酯 | CAS号928-51-8 4-氯-1-丁醇 | CAS号74-89-5 氨基甲烷 | CAS号67-56-1 甲醇 | CAS号6976-17-6 4-(甲胺)丁酸盐酸盐 | CAS号110-63-4 1,4-丁二醇(BDO) | CAS号1191-99-7 2,3-二氢呋喃 | CAS号120-94-5 1-甲基吡咯烷 | CAS号13330-96-6 4-二甲氨基-1-丁醇 | CAS号91735-37-4 N-(4-chlorobuty... | CAS号99207-32-6 N-B°C-N-甲基-4-氨甲丁醇 | CAS号51938-16-0 N-METHYL-N-(4-H...

📜4-Ethoxycarbonylaminobutanol置于lithium Aluminium Tetrahydride体系中,用 四氢呋喃 作为反应溶剂,化学反应 1.5H,以58%的收率获得产物4-甲基氨基丁醇
参考文献:Selexipag:口服和选择性ip前列环素受体激动剂,用于治疗肺动脉高压
标题:Selexipag:口服和选择性ip前列环素受体激动剂,用于治疗肺动脉高压
摘要:前列环素通过前列环素受体的激活来控制心血管功能.前列环素产生的减少发生在几种心血管疾病中.然而,前列环素及其类似物的临床使用由于其化学和代谢不稳定而变得复杂.一项药物化学程序正在寻找不受这些限制的新型非前列腺素类前列环素受体激动剂.合成具有二苯基吡嗪结构核心的化合物.通过修饰线性侧链优化了代谢稳定性和激动剂效能.化合物12B(mre-269,Act-333679)被鉴定为有效且高度选择性的前列环素受体激动剂.用n取代末端羧基-酰基磺酰胺基产生母体化合物26A(selexipag,Ns-304,Act-293987),该化合物具有口服活性,并提供持续的12B血浆暴露.化合物26A被开发用于治疗肺动脉高压,并在3期事件驱动的临床试验中显示出降低复合发病率/死亡率终点的风险.
DOI:10.1021/acs.Jmedchem.5B00698

专利信息

专利号:US-8557979-B2
优先权日:2004-06-10
标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation
发明人：CHOI WOO-BAEG; KOWALIK EWA
权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC
摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

专利号:US-10933051-B2
优先权日:2017-06-09
标 题 :Carbapenem compounds and compositions for the treatment of bacterial infections
发明人：CHOI WOO-BAEG; TOMIOKA TAKASHI; JOO HYUNG-YEUL; TRUONG PHONG; MIN BRIAN
权利人:FOB SYNTHESIS INC
摘要:The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

专利号:US-9937151-B2
优先权日:2010-06-18
标题 :Carbapenem antibacterials with gram-negative activity
发明人：CHOI WOO-BAEG; GRUSZECKA-KOWALIK EWA; JOO HYUNG-YEUL; LIU SHUANGPEI; MAO SHULI; LI YONGFENG; KIM DEOG-IL
权利人:FOB SYNTHESIS INC
摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

专利号:EP-4520765-A1
优先权日:2023-09-08
标题:Ionizable cationic lipids incorporating silicon
发明人：RÉPÃ?SI JÓZSEF; SZILVÃ?GYI GÃ?BOR
权利人:ALDEXCHEM KFT
摘要:The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls.The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil^â„¢ 2^nd generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts [WO 2022/129966]. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, circular DNA, small biologically active molecules) into the cells.